Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.

Ronceray L, Dworzak M, Dieckmann K, Ebetsberger-Dachs G, Glogova E, Haas OA, Jones N, Nebral K, Moser R, Lion T, Meister B, Panzer-Grümayer R, Strehl S, Peters C, Pötschger U, Urban C, Mann G, Attarbaschi A, Austrian Berlin-Frankfurt-Münster (BFM) Study Group

Open source

DOI: 10.1007/s00508-023-02249-6
Published: 2024 Jul
Container: Wiener klinische Wochenschrift
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00508-023-02249-6,
  title = {Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.},
  author = {Ronceray L and Dworzak M and Dieckmann K and Ebetsberger-Dachs G and Glogova E and Haas OA and Jones N and Nebral K and Moser R and Lion T and Meister B and Panzer-Grümayer R and Strehl S and Peters C and Pötschger U and Urban C and Mann G and Attarbaschi A and Austrian Berlin-Frankfurt-Münster (BFM) Study Group},
  year = {2024},
  journal = {Wiener klinische Wochenschrift},
  doi = {10.1007/s00508-023-02249-6},
  url = {https://doi.org/10.1007/s00508-023-02249-6}
}

RIS

TY  - JOUR
TI  - Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
AU  - Ronceray L
AU  - Dworzak M
AU  - Dieckmann K
AU  - Ebetsberger-Dachs G
AU  - Glogova E
AU  - Haas OA
AU  - Jones N
AU  - Nebral K
AU  - Moser R
AU  - Lion T
AU  - Meister B
AU  - Panzer-Grümayer R
AU  - Strehl S
AU  - Peters C
AU  - Pötschger U
AU  - Urban C
AU  - Mann G
AU  - Attarbaschi A
AU  - Austrian Berlin-Frankfurt-Münster (BFM) Study Group
PY  - 2024
JO  - Wiener klinische Wochenschrift
DO  - 10.1007/s00508-023-02249-6
UR  - https://doi.org/10.1007/s00508-023-02249-6
ER  -

APA

L, R., M, D., K, D., G, E., E, G., OA, H., N, J., K, N., R, M., T, L., B, M., R, P., S, S., C, P., U, P., C, U., G, M., A, A., & Group, A. B. (. S. (2024). Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-023-02249-6

Source records

pubmed · retrieved 2026-09-27T10:16:19.956Z